Skip to content

Clinical trials

Lipid Metabolism Disorders trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lipid Metabolism Disorders Clear all

176 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20022
20031
20041
20065
20075
20084
20091
20104
20116
20122
20136
201411
20155
20167
201715
20188
20199
202013
20219
202214
202315
202416
20256
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed106
Unknown status25
Recruiting22
Active, not recruiting8
Not yet recruiting7
Withdrawn3
Terminated2
No longer available1
Suspended1
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Pfizer6
Kastle Therapeutics, LLC5
University of Texas Southwestern Medical Center5
Akcea Therapeutics4
University of Colorado, Denver3
4D Molecular Therapeutics2
89bio, Inc.2
All India Institute of Medical Sciences, Bhubaneswar2
BTL Industries Ltd.2
CENTOGENE GmbH Rostock2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lipid Metabolism Disorders176
Dyslipidemias41
Metabolic Diseases40
Hyperlipidemias27
Obesity25
Hypercholesterolemia23
Cardiovascular Diseases21
Glucose Metabolism Disorders18
Genetic Diseases, Inborn16
Hypertriglyceridemia13

Trials

Showing 1 to 25 of 176. Each trial links to its page on Pharma Observatory.

76 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.